Smithsonian's "Bionic Man" TV Special and Exhibit Feature the SynCardia Total Artificial Heart
Documentary States the SynCardia Heart is the Only Manmade Internal Organ That's Already Saving Lives
Scientists and roboticists researched and used the most advanced technology they could find to build the 2013 version of the bionic man, complete with prosthetic body parts and manmade organs. The documentary and complimentary museum exhibits are part of a collaborative effort that includes the Smithsonian Museum, London's Science Museum, the Smithsonian Cable Channel and England's Channel 4.
The high-tech cyborg named "Rex," whose creation is documented in "The Incredible Bionic Man" television special and which has been moved from England to the Smithsonian Museum, not only has a skeletal frame with artificial limbs, but a heart, pancreas, lung, spleen and kidney.
"Many of these (organs) are still prototypes," says the show's narrator, Dr. Bertholt Meyer. "The hope is that one day they'll solve the worldwide shortage of donor organs, but the (SynCardia) Artificial Heart is already saving lives."
As the world's first and only FDA, Health Canada and CE approved Total Artificial Heart, the SynCardia Heart has been implanted in more than 1,200 patients worldwide. That accounts for more than 335 patient years of life on the device. Like a donor heart, the SynCardia Heart is the only device that eliminates the symptoms and source of end-stage biventricular heart failure. Unlike a donor heart, the SynCardia Heart is immediately available at 87 SynCardia Certified Centers worldwide with 33 others in the process of certification.
Today there are more than 3,000 Americans on a wait list for a donor heart transplant. Each year approximately 14-16 percent become too ill or die waiting for a donor heart. The SynCardia Total Artificial Heart is a bridge to transplant for patients suffering from end-stage heart failure affecting both sides of the heart (biventricular failure).
The exhibit will be at the Smithsonian National Air and Space Museum. "The Incredible Bionic Man" documentary will debut on the Smithsonian Channel at 9 p.m. Eastern and Pacific times on Sunday, Oct. 20. It shows the surgical implantation of the SynCardia Total Artificial Heart into a U.S. patient.
"The Artificial Heart is made of two chambers that replace the heart's two ventricles, the work horse that pumps 2,000 gallons of blood a day," says Meyer. "With all that work to do, the Artificial Heart has to be tough and durable. Its valves are titanium and its chambers are reinforced polymers."
The SynCardia Total Artificial Heart in "Rex" is powered by the Freedom® portable driver. Once a patient's condition becomes stable, they are switched to the Freedom. With this 13.5-pound wearable power supply, patients can be discharged from the hospital to wait for a donor human heart at home and in their communities.
"We are proud that the SynCardia Total Artificial Heart is part of this documentary that shows the most advanced technology that can help humans live longer, healthier lives," says Michael P. Garippa, SynCardia Systems Inc. CEO and president.
SynCardia Systems Inc
SynCardia Systems, Inc. (Tucson AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers.
It is the only device that eliminates the symptoms and source of end-stage biventricular failure.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.
For additional information, please visit: http://www.syncardia.com
Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Splunk unterstützt Amazon Kinesis Firehose und GuardDuty
Der Machine-Learning-Spezialist Splunk ist eine strategische Zusammenarbeit mit Amazon Web Services (AWS) eingegangen. Ab sofort sind Integrationen in Amazon Kinesis Firehose und GuardDuty verfügbar.Weiterlesen